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Background: Among human host factors known to modulate
HIV disease progression, the C-type lectins, dendritic cell-speciﬁc
intercellular adhesionmolecule-3-grabbing non-integrin, DC-SIGN
and the liver/lymph node-speciﬁc L-SIGN have been poorly
described in children with HIV. We aimed to study the exon 4
repeat-region polymorphisms, and assess the impact of DC/L-SIGN
homozygous and heterozygous genotypes among pediatric slow
and rapid progressors.
Methods & Materials: We deﬁned slow progressor children as
perinatally-infected, asymptomatic, with known HIV infection for
>10yrs, ART-naïve, and CD4>500 cells/mm3 and rapid/normal pro-
gressors as HIV infection<10 years, on ART, CD4<500 cells/mm3.
Genomic DNA isolated from whole blood was genotyped for DC/L-
SIGN exon 4 tandem repeat-region variants by PCR.
Results: Among 25 slow progressors included, mean age
was 10.8±2.42 years, 64% females, median CD4 count was 751
cells/mm3 (IQR575-1036.75) andviral load, 4.36 log copies/ml (IQR
4.09-4.84). Among 40 rapid progressors, mean age was 6.07±2.4
years, 45% females, median CD4 was 462.5 cells/mm3 (IQR 291-
663) and viral load, 5.42 log copies/ml (IQR 4.97-5.95). The exon-4
repeat-region DC-SIGN polymorphism was not observed in our
population as all samples showed 7/7 homozygous DC-SIGN geno-
type. In the L-SIGN repeat region, eight genotypes were found.
The total L-SIGN heterozygosity in slow (7/5, 7/6, 9/5, 9/6 and 9/7
genotypes) and rapid (6/5, 7/5, 7/6, 9/5, 9/6 and 9/7 genotypes)
progressors was 76% and 45% respectively (P=0.02; OR=3.87; 95%CI
1.3-11.7). Rapid progressors had a signiﬁcantly higher occurance
of 7/7 homozygous L-SIGN genotype (P=0.03; OR=3.5; 95%CI=1.16-
10.6). The L-SIGN allele frequency in slow progressors was 14% for
allele 5, 14% for allele 6, 54% for allele 7 and 18% for allele 9. L-SIGN
alleles 6 and 7 were signiﬁcantly more frequent in rapid progres-
sors than slow progressors (P=0.03, OR=0.16, 95%CI=0.03-0.8 and
P=0.03, OR=2.24, 95%CI=1.07-4.72 respectively).
Conclusion: This is theﬁrst study todetermine theDC-SIGNand
L-SIGN polymorphisms in HIV-1 positive children in India. While
heterozygous DC-SIGN genotypeswere not seen in this population,
the higher prevalence of heterozygous L-SIGN genotypes among
slow progressors suggests their protective role in HIV disease pro-
gression among children in India.
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Background: Uganda like most countries is providing Option
B+ to HIV+ mothers. However, patients who start ART with a high
immunity are often thought to be poorly retained in care (Tayler et
al, 2010). Poor retention in care predicts poorer survival with HIV
infection (Thomas et al, 2007). Patients with CD4 >350 cells/L are
asymptomatic and presumed to be comfortable with their status
quo. The study hypothesized that CD4 <350 cell/l at initiation of
Option B+ would also predict higher retention compared to CD4
>350 cell/l.
Methods&Materials: A retrospective cohort studywasdoneon
mothers that were initiated on Option B+ between December 2012
and January 2013 in six urban public health facilities in Uganda.
Patients were observed starting at Option B+ initiation to patient
outcome such as at death, transfer out, loss to follow-up and 12
months after initiation. Only mothers whose CD4 was recorded at
initiation of Option B+ were considered for analysis.
Results: A total of 601 mothers with mean age 25.0 years (95%
CI: 21-28) were enrolled and of these 65% were still in care one
year after option B+ initiation. At the time of enrollment, 313moth-
ers had CD4 > 350, 74 had CD4 <350 while 212 had no CD4 done.
Majority, (80%) mothers had no prior exposure to ARVs at the time
of initiation. There was a signiﬁcant relationship between reten-
tion and prior treatment, age of mother > 20yrs, and CD4 levels.
After regression modelling, the odds of being in care among CD4
>350 were 2.21 (p=005) times more likely to stay in care compared
to those with lower CD4. There was no signiﬁcant relationship
between retention and age or prior ART.
Conclusion: Contrary to the study hypothesis and knowledge
among the general HIV patients, our study revealed that women
started on option B+ with CD4 >350 cell/ul were 2.21 times more
likely to stay in care, one year after ART initiation.
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